These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 33670634)

  • 1. Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Paderi A; Giorgione R; Giommoni E; Mela MM; Rossi V; Doni L; Minervini A; Carini M; Pillozzi S; Antonuzzo L
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33670634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
    Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab.
    Ishihara H; Takagi T; Kondo T; Homma C; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Urol Oncol; 2019 Jun; 37(6):355.e21-355.e29. PubMed ID: 30935847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
    Ikeda T; Ishihara H; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Takagi T; Iizuka J; Hashimoto Y; Ishida H; Kondo T; Tanabe K
    Urol Oncol; 2021 Oct; 39(10):735.e9-735.e16. PubMed ID: 34172370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
    Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
    Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis.
    Sun Q; Sun H; Wu N; Hu Y; Zhang F; Cong X
    Front Oncol; 2022; 12():976224. PubMed ID: 36185176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic impact of immune-related adverse events in metastatic renal cell carcinoma patients treated with nivolumab: a real-world multi-institutional retrospective study.
    Kato T; Nagahara A; Kawamura N; Nakata W; Soda T; Matsuzaki K; Hatano K; Kawashima A; Ujike T; Imamura R; Nishimura K; Takada S; Tsujihata M; Yamaguchi S; Takao T; Nishimura K; Nonomura N; Uemura M
    Int J Clin Oncol; 2021 May; 26(5):954-961. PubMed ID: 33471290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study.
    Nukaya T; Takahara K; Yoshizawa A; Saruta M; Yano Y; Ohno T; Uchimoto T; Fukuokaya W; Adachi T; Yamazaki S; Tokushige S; Nishimura K; Tsujino T; Nakamori K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Hirasawa Y; Hashimoto T; Komura K; Inamoto T; Miki J; Kimura T; Ohno Y; Azuma H; Shiroki R
    Clin Genitourin Cancer; 2024 Feb; 22(1):76-83. PubMed ID: 37880020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
    Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
    BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
    Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis.
    Washino S; Shirotake S; Takeshita H; Inoue M; Miura Y; Hyodo Y; Kagawa M; Izumi K; Oyama M; Kawakami S; Saito K; Matsuoka Y; Taniuchi S; Shintani A; Miyagawa T
    Int J Clin Oncol; 2023 Dec; 28(12):1651-1658. PubMed ID: 37658926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients.
    Kankkunen E; Penttilä P; Peltola K; Bono P
    Acta Oncol; 2022 Oct; 61(10):1240-1247. PubMed ID: 35905053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Significance of Immune-related Adverse Events in Metastatic Renal Cell Carcinoma Patients Treated With Immune-checkpoint-inhibitors.
    Yasuda Y; Fujiwara R; Oguchi T; Komai Y; Numao N; Yamamoto S; Oki R; Urasaki T; Takahashi S; Yonese J; Yuasa T
    Cancer Diagn Progn; 2023; 3(3):327-333. PubMed ID: 37168959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Zhang Y; Chen J; Liu H; Dai J; Zhao J; Zhu S; Zhang X; Liang J; Hu X; Zhao J; Liu Z; Shen P; Sun G; Zeng H
    Cancer Treat Rev; 2024 Sep; 129():102787. PubMed ID: 38905806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.
    Verzoni E; Cartenì G; Cortesi E; Giannarelli D; De Giglio A; Sabbatini R; Buti S; Rossetti S; Cognetti F; Rastelli F; Sobrero A; Turci D; Sternberg CN; Porta C; Cappuzzo F; Tortora G; Tassinari D; Panni S; Pazzola A; Surico G; Raimondi A; De Giorgi U; Procopio G;
    J Immunother Cancer; 2019 Apr; 7(1):99. PubMed ID: 30944023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
    Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis.
    Zhou X; Yao Z; Yang H; Liang N; Zhang X; Zhang F
    BMC Med; 2020 Apr; 18(1):87. PubMed ID: 32306958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study.
    Vitale MG; Pipitone S; Venturelli M; Baldessari C; Porta C; Iannuzzi F; Basso U; Scagliarini S; Zucali PA; Galli L; Rossetti S; Caserta C; Bracarda S; Iacovelli R; Masini C; Cortellini A; Di Girolamo S; Buti S; Fornarini G; Carrozza F; Santoni M; Caputo F; Giaquinta S; Balduzzi S; D'Amico R; Vitale G; Mighali P; Sabbatini R
    Clin Genitourin Cancer; 2020 Dec; 18(6):477-488. PubMed ID: 32732112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
    Fukushima T; Morimoto M; Kobayashi S; Ueno M; Uojima H; Hidaka H; Kusano C; Chuma M; Numata K; Tsuruya K; Arase Y; Kagawa T; Hattori N; Ikeda H; Watanabe T; Tanaka K; Maeda S
    Oncologist; 2023 Jul; 28(7):e526-e533. PubMed ID: 37023703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.